AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28806904 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 150
Study 26098128 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosa damascena oil
Number of subjects: 50
Study 26098128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26866103 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with omega 3 fatty acid solution (S-O group)
Number of subjects: 36
Study 26866103 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with glutamine solution (S-D group)
Number of subjects: 36
Study 26866103 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with omega 3 fatty acids solution and glutamine (S-D-O group)
Number of subjects: 36
Study 26866103 — intervention group
Group type: COMPARATOR
Intervention: Standard TPN (Control group)
Number of subjects: 36
Study 26866103 — intervention group
Group type: EXPERIMENTAL
Intervention: All study groups (including S-D, S-O, S-D-O)
Number of subjects: 36
Study 26866103 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study 21384285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=22) received a home visit by a HF-nurse and 17 telephone calls over 12 months focusing on self-care.
Number of subjects: 42
Study 21384285 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (n=20) received standard medical treatment and lifestyle recommendations without additional support.
Number of subjects: 42
Study 21384285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=22)
Number of subjects: 42
Study 21384285 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (n=20)
Number of subjects: 42
Study 19730881 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain placement
Number of subjects: 160
Study 19730881 — intervention group
Group type: COMPARATOR
Intervention: No drain placement
Number of subjects: 160
Study 17277576 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-of-five technique (direct cortical stimulation)
Number of subjects: 129
Study 17277576 — intervention group
Group type: COMPARATOR
Intervention: 60-Hz technique (direct cortical stimulation)
Number of subjects: 129
Study 17277576 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without symptomatic epilepsy)
Number of subjects: 129
Study 15015439 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiawei Yupingfeng Powder (JYP) administered additionally for 14 days
Number of subjects: 84
Study 15015439 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicinal therapy
Number of subjects: 84
Study 15015439 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiawei Yupingfeng Powder (JYP)
Number of subjects: 84
Study 11440911 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake (1.5 g x kg(‐1) x day(‐1))
Number of subjects: 12
Study 11440911 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein intake (0.3 g. kg(‐1) x day(‐1))
Number of subjects: 12
Study 11440911 — intervention group
Group type: COMPARATOR
Intervention: Customary high-protein diet (for diabetic subjects)
Number of subjects: 12
Study 9602576 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine mixed with 1% propofol
Number of subjects: 50
Study 9602576 — intervention group
Group type: COMPARATOR
Intervention: Morphine mixed with lvelip
Number of subjects: 50
Study 7800581 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (MI) 400 mg
Number of subjects: 15
Study 7800581 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 15
Study 3055791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (2 mg/kg) administered intraperitoneally 10 min before surgery (n = 9)
Number of subjects: 19
Study 3055791 — intervention group
Group type: COMPARATOR
Intervention: Saline administered intraperitoneally (n = 10)
Number of subjects: 19
Study 3055791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (2 mg/kg)
Number of subjects: 19
Study 3055791 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 19
Study 29990679 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile video-based CBT
Number of subjects: 5
Study 27931552 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 35mg sustained release tablet, twice daily
Number of subjects: 98
Study 27931552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 25262254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 913
Study 25262254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 913
Study 23328596 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (1 year)
Number of subjects: 122
Study 23328596 — intervention group
Group type: COMPARATOR
Intervention: Observation (1 year)
Number of subjects: 122
Study 19951297 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention with ethnic match
Number of subjects: 537
Study 19951297 — intervention group
Group type: COMPARATOR
Intervention: Brief motivational intervention without ethnic match
Number of subjects: 537
Study 19951297 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 537
Study 18096287 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone 6 mg/day plus propentofylline 900 mg/day (300 mg TDS)
Number of subjects: 50
Study 18096287 — intervention group
Group type: COMPARATOR
Intervention: risperidone 6 mg/day plus placebo
Number of subjects: 50
Study 15669881 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (tenofovir DF) 300 mg once daily
Number of subjects: 0
Study 12428176 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron supplementation (11.6 mg boron as 102.6 mg sodium tetraborate decahydrate)
Number of subjects: 15
Study 12428176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12428176 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron supplementation (11.6 mg boron)
Number of subjects: 15
Study 10350016 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie protein meal
Number of subjects: 7
Study 10350016 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie carbohydrate meal
Number of subjects: 7
Study 10350016 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie fat meal
Number of subjects: 7
Study 10350016 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-caloric hydroxypropylmethyl cellulose (HPMC) viscous meal
Number of subjects: 7
Study 10350016 — intervention group
Group type: COMPARATOR
Intervention: Fasted control
Number of subjects: 7
Study 8647571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Number of subjects: 10
Study 8647571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba combined with walking exercise
Number of subjects: 10
Study 1685362 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (diuretic)
Number of subjects: 0
Study 1685362 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (alpha 1‐blocker)
Number of subjects: 0
Study 1685362 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release nifedipine (calcium blocker)
Number of subjects: 0
Study 6158478 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ 20,881
Number of subjects: 31
Study 6158478 — intervention group
Group type: COMPARATOR
Intervention: SQ 14,225
Number of subjects: 31
Study 30789027 — intervention group
Group type: EXPERIMENTAL
Intervention: RCC training program alone
Number of subjects: 92
Study 30789027 — intervention group
Group type: EXPERIMENTAL
Intervention: RCC training program plus support
Number of subjects: 92
Study 30789027 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 92
Study 30548889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training in reasoning, processing speed, memory
Number of subjects: 2802
Study 30548889 — intervention group
Group type: COMPARATOR
Intervention: No-contact control condition
Number of subjects: 2802
Study 27472929 — intervention group
Group type: EXPERIMENTAL
Intervention: 130g/day low-carbohydrate diet (LCD)
Number of subjects: 66
Study 27472929 — intervention group
Group type: COMPARATOR
Intervention: Calorie restricted diet (CRD)
Number of subjects: 66
Study 26291542 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged cycling training (15 minutes with each leg, three times per week for 6-8 weeks)
Number of subjects: 22
Study 26291542 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged cycling training
Number of subjects: 22
Study 23803893 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular activity breaks (walking for 1 min 40 s every 30 min)
Number of subjects: 70
Study 23803893 — intervention group
Group type: COMPARATOR
Intervention: Physical activity (walking for 30 min and then sitting)
Number of subjects: 70
Study 21852659 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school health education and physical activity program (12 weeks, twice a week)
Number of subjects: 901
Study 21852659 — intervention group
Group type: COMPARATOR
Intervention: Spillover effects from intervention participants to nonparticipants
Number of subjects: 901
Study 19297786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic wound compression
Number of subjects: 288
Study 19297786 — intervention group
Group type: COMPARATOR
Intervention: No compression (control)
Number of subjects: 288
Study 17173278 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (16 microg) alone (regimen A)
Number of subjects: 26
Study 17173278 — intervention group
Group type: COMPARATOR
Intervention: Paricalcitol (16 microg) with omeprazole (40 mg) (regimen B)
Number of subjects: 26
Study 15887905 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously injured players (ankle or knee ligament injury)
Number of subjects: 216
Study 15887905 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously injured limb
Number of subjects: 216
Study 15887905 — intervention group
Group type: COMPARATOR
Intervention: Players with no previous lower limb ligament injury
Number of subjects: 216
Study 12926190 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 15
Study 12926190 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 15
Study 12926190 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 15
Study 12926190 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 15
Study 12926190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 15
Study 12926190 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate
Number of subjects: 15
Study 12926190 — intervention group
Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 15
Study 12926190 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin
Number of subjects: 15
Study 12926190 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam
Number of subjects: 15
Study 12926190 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 15
Study 12926190 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophilia
Number of subjects: 15
Study 12926190 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated liver enzymes
Number of subjects: 15
Study 12926190 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin biopsies
Number of subjects: 15
Study 10682457 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg/daily for 3 months
Number of subjects: 20
Study 10682457 — intervention group
Group type: COMPARATOR
Intervention: Control (no mifepristone treatment)
Number of subjects: 20
Study 7741987 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal surgical endeavour aimed at cytoreduction
Number of subjects: 0
Study 7741987 — intervention group
Group type: COMPARATOR
Intervention: Standard practice of cytoreduction
Number of subjects: 0
Study 2616602 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg
Number of subjects: 9
Study 2616602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2616602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine 40 mg IV
Number of subjects: 9
Study 84761 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide (Pronestyl)
Number of subjects: 18
Study 84761 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylprocainamide (Duretter)
Number of subjects: 18
Study 28462467 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based attenuation correction (AC)
Number of subjects: 312
Study 28462467 — intervention group
Group type: COMPARATOR
Intervention: Non-AC (NAC)
Number of subjects: 312
Study 29236569 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-way text messaging engagement during the first 2 weeks postpartum
Number of subjects: 0
Study 27399141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole-based regimen
Number of subjects: 200
Study 27399141 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole-based regimen
Number of subjects: 200
Study 23625140 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement and collaborative planning intervention
Number of subjects: 0
Study 22906943 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine (3.8 µg or 7.5 µg HA)
Number of subjects: 0
Study 22906943 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (15 µg HA)
Number of subjects: 0
Study 22906943 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine (1.9 µg or 3.8 µg HA)
Number of subjects: 0
Study 22906943 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (7.5 µg HA)
Number of subjects: 0
Study 22906943 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine
Number of subjects: 0
Study 19374793 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem restriction
Number of subjects: 26
Study 19374793 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 26
Study 17573885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% (twice daily) + Fluticasone propionate cream 0.05% (once daily)
Number of subjects: 45
Study 17573885 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (twice daily) + Fluticasone propionate cream 0.05% (once daily)
Number of subjects: 45
Study 15068193 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive software
Number of subjects: 16
Study 15068193 — intervention group
Group type: COMPARATOR
Intervention: Current head-control system
Number of subjects: 16
Study 11842880 — intervention group
Group type: EXPERIMENTAL
Intervention: 300mg S-PS daily
Number of subjects: 120
Study 11842880 — intervention group
Group type: EXPERIMENTAL
Intervention: 600mg S-PS daily
Number of subjects: 120
Study 11842880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9543974 — intervention group
Group type: EXPERIMENTAL
Intervention: Combine dressing pad
Number of subjects: 36
Study 9543974 — intervention group
Group type: COMPARATOR
Intervention: Calcium alginate
Number of subjects: 36
Study 9543974 — intervention group
Group type: COMPARATOR
Intervention: Sodium hypochlorite (0.05%)
Number of subjects: 36
Study 8067557 — intervention group
Group type: EXPERIMENTAL
Intervention: eltanolone
Number of subjects: 60
Study 8067557 — intervention group
Group type: COMPARATOR
Intervention: propofol
Number of subjects: 60
Study 3141755 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (three times a day)
Number of subjects: 6
Study 3141755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31663412 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette addressing individual as 'suffering from substance use disorder'
Number of subjects: 184
Study 31663412 — intervention group
Group type: COMPARATOR
Intervention: Vignette addressing individual as an 'addict'
Number of subjects: 184
Study 31663412 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (Women)
Number of subjects: 184
Study 29056601 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi‐automated volume measurements
Number of subjects: 2240
Study 29056601 — intervention group
Group type: COMPARATOR
Intervention: Mean axial diameter
Number of subjects: 2240
Study 29056601 — intervention group
Group type: COMPARATOR
Intervention: Maximum axial diameter
Number of subjects: 2240
Study 28208006 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS‐FNB
Number of subjects: 58
Study 28208006 — intervention group
Group type: COMPARATOR
Intervention: EUS‐FNA
Number of subjects: 58
Study 25742205 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (1,998 mg/d orally)
Number of subjects: 327
Study 25742205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 23108604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/tadalafil 5 mg
Number of subjects: 40
Study 23108604 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg/placebo
Number of subjects: 40
Study 21677574 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 62
Study 21677574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 18297270 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM‐ICU assessments by bedside nurses
Number of subjects: 1011
Study 18297270 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM‐ICU assessments by bedside nurses in TBI patients
Number of subjects: 1011
Study 18297270 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM‐ICU assessments by bedside nurses in mechanically ventilated patients
Number of subjects: 1011
Study 18297270 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-implementation survey of nurses
Number of subjects: 1011
Study 16539548 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind map
Number of subjects: 30
Study 16539548 — intervention group
Group type: EXPERIMENTAL
Intervention: Acronym
Number of subjects: 30
Study 16539548 — intervention group
Group type: COMPARATOR
Intervention: Information leaflet
Number of subjects: 30
Study 14737726 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy with (131)I at doses ranging from 5‐200 mCi
Number of subjects: 0
Study 16227794 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine (NVP) administered to mothers at labor onset and to infants within 72 hours of birth.
Number of subjects: 1491
Study 16227794 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine (NVP) administered to infants < 4 hours after birth.
Number of subjects: 1491
Study 16227794 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine (NVP) administered to mothers within 24 hours of delivery.
Number of subjects: 1491
Study 16227794 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine (NVP) administered to infants within 48 hours after delivery.
Number of subjects: 1491
Study 10352203 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L exchange volume
Number of subjects: 20
Study 10352203 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 L exchange volume
Number of subjects: 20
Study 10352203 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 L exchange volume
Number of subjects: 20
Study 10352203 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal clearances of creatinine
Number of subjects: 20
Study 10352203 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal clearances of urea nitrogen
Number of subjects: 20
Study 9012296 — intervention group
Group type: EXPERIMENTAL
Intervention: 3xED95 cisatracurium
Number of subjects: 62
Study 9012296 — intervention group
Group type: EXPERIMENTAL
Intervention: 5xED95 cisatracurium
Number of subjects: 62
Study 9012296 — intervention group
Group type: COMPARATOR
Intervention: 3xED90 vecuronium
Number of subjects: 62
Study 2045027 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic visual acuity test using an LCD screen with 400 x 640 pixel display of Landolt rings.
Number of subjects: 0
Study 2045027 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing of visual acuity at short time intervals.
Number of subjects: 0
Study 2045027 — intervention group
Group type: EXPERIMENTAL
Intervention: Delegation of the test to support personnel.
Number of subjects: 0
Study 7272706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 42
Study 7272706 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 42
Study 30462199 — intervention group
Group type: EXPERIMENTAL
Intervention: MR using Gene‐by‐Environment interactions (MRGxE)
Number of subjects: 0
Study 27984024 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine 1.25% ophthalmic solution
Number of subjects: 172
Study 27984024 — intervention group
Group type: COMPARATOR
Intervention: Topical antibiotics (neomycin-polymyxin B-gramicidin in the Philippines; ciprofloxacin 0.3% in India)
Number of subjects: 172
Study 27984024 — intervention group
Group type: COMPARATOR
Intervention: Topical antibiotics
Number of subjects: 172
Study 25471330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg plus single standard verteporfin PDT
Number of subjects: 40
Study 25471330 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0.3 mg plus sham PDT
Number of subjects: 40
Study 25125237 — intervention group
Group type: EXPERIMENTAL
Intervention: Video featuring a pediatric transplant recipient (with or without sound)
Number of subjects: 781
Study 25125237 — intervention group
Group type: EXPERIMENTAL
Intervention: All six videos (including the pediatric transplant recipient video)
Number of subjects: 781
Study 25125237 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority race
Number of subjects: 781
Study 25125237 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive change in organ donor readiness
Number of subjects: 781
Study 25125237 — intervention group
Group type: EXPERIMENTAL
Intervention: Total positive emotion
Number of subjects: 781
Study 22621716 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan intervention group (n = 2,052)
Number of subjects: 4104
Study 22621716 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 2,052)
Number of subjects: 4104
Study 19805698 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone care management intervention (up to 5 outreach calls for monitoring and support)
Number of subjects: 600
Study 19805698 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management plus telephone psychotherapy intervention (8-session structured cognitive behavioral therapy program with up to 4 additional calls)
Number of subjects: 600